ReviewJournal of veterinary internal medicine
Oral cyclosporine treatment in dogs: a review of the literature.
Review in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 104 citations in OpenAlex.
- The Effects of Cyclosporine and Aspirin on Platelet Function in Normal Dogs.Journal of veterinary internal medicine · 2016Trial
- Effects of oral cyclosporine on canine T-cell expression of IL-2 and IFN-gamma across a 12-h dosing interval.Journal of veterinary pharmacology and therapeutics · 2016Trial
- Cyclosporine as a Novel Therapeutic Option for Eosinophilic Cystitis in a Paraplegic Dog.Case reports in veterinary medicine · 2026Article
- Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis.International journal of molecular sciences · 2025Review
- Acquired Myasthenia Gravis in a Juvenile Australian Shepherd Dog and Efficacy of Leflunomide Treatment.Case reports in veterinary medicine · 2025Article
- Canine Atopic Dermatitis: Prevalence, Impact, and Management Strategies.Veterinary medicine (Auckland, N.Z.) · 2024Review
- Porcine-human glioma xenograft model. Immunosuppression and model reproducibility.Cancer treatment and research communications · 2024Article
- Retrospective evaluation of prognosis and survival with various immunosuppressants in 82 dogs diagnosed with meningoencephalitis of unknown etiology (2010-2021).BMC veterinary research · 2023Article
- The Pharmacokinetic and Absolute Bioavailability of Cyclosporine (Atopica for CatsVeterinary sciences · 2023Article
- Perspectives on pharmacologic strategies in the management of meningoencephalomyelitis of unknown origin in dogs.Frontiers in veterinary science · 2023Review
- The Intersection of Human and Veterinary Medicine-A Possible Direction towards the Improvement of Cell Therapy Protocols in the Treatment of Perianal Fistulas.International journal of molecular sciences · 2022Review
- New insights into the etiology, risk factors, and pathogenesis of pancreatitis in dogs: Potential impacts on clinical practice.Journal of veterinary internal medicine · 2022Review
- A Retrospective Evaluation of the Steroid-Sparing Effect of Oral Modified Ciclosporin for Treatment of Canine Pemphigus Foliaceus.Veterinary sciences · 2022Article
- Pharmacokinetics and bioequivalence of two cyclosporine oral solution formulations in cats.Frontiers in veterinary science · 2022Article
- Current Knowledge on Canine Atopic Dermatitis: Pathogenesis and Treatment.Advances in small animal care · 2021Article
- Cyclosporine Treatment in Cats with Presumed Chronic Pancreatitis-A Retrospective Study.Animals : an open access journal from MDPI · 2021Article
- Recovery of T-cell function in healthy dogs following cessation of oral cyclosporine administration.Veterinary medicine and science · 2020Article
- Ehrlichia canis in dogs experimentally infected, treated, and then immune suppressed during the acute or subclinical phases.Journal of veterinary internal medicine · 2020Article
- Identification of Dermatophyte and Nondermatophyte Molds Isolated from Animal Lesions Suspected to Dermatomycoses.Advanced biomedical research · 2020Article
- Pharmacodynamic assessment ofCanadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclosporine is an immunomodulatory drug used to treat an increasing spectrum of diseases in dogs. Cyclosporine is a calcineurin inhibitor, ultimately exerting its inhibitory effects on T-lymphocytes by decreasing production of cytokines, such as interleukin-2. Although, in the United States, oral cyclosporine is approved in dogs only for treatment of atopic dermatitis, there are many other indications for its use. Cyclosporine is available in 2 oral formulations: the original oil-based formulation and the more commonly used ultramicronized emulsion that facilitates oral absorption. Ultramicronized cyclosporine is available as an approved animal product, and human proprietary and generic preparations are also available. Bioavailability of the different formulations in dogs is likely to vary among the preparations. Cyclosporine is associated with a large number of drug interactions that can also influence blood cyclosporine concentrations. Therapeutic drug monitoring (TDM) can be used to assist in attaining consistent plasma cyclosporine concentrations despite the effects of varying bioavailability and drug interactions. TDM can facilitate therapeutic success by guiding dose adjustments on an individualized basis, and is recommended in cases that do not respond to initial oral dosing, or during treatment of severe, life-threatening diseases for which a trial-and-error approach to dose adjustment is too risky. Pharmacodynamic assays that evaluate individual patient immune responses to cyclosporine can be used to augment information provided by TDM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.